These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9259190)

  • 1. Studies on the efficacy and prognostic significance of drug therapy of ventricular tachyarrhythmias.
    Borchard U; Manz M
    Herz; 1997 Jun; 22 Suppl 1():1-2. PubMed ID: 9259190
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti-arrhythmia drugs].
    Haverkamp W; Borggrefe M; Block M; Böcker D; Breithardt G
    Z Kardiol; 1996; 85 Suppl 6():97-106. PubMed ID: 9064989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Characteristics of drug-refractory sustained ventricular tachycardia].
    Sakurada H; Hiyoshi Y; Okazaki H; Tejima T; Motomiya T; Sugiura M; Nishizaki M; Arita M; Hiraoka M
    Jpn Circ J; 1992; 56 Suppl 5():1462-4. PubMed ID: 1291743
    [No Abstract]   [Full Text] [Related]  

  • 4. Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment.
    Kühlkamp V; Mewis C; Mermi J; Bosch RF; Seipel L
    J Am Coll Cardiol; 1999 Jan; 33(1):46-52. PubMed ID: 9935007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of trends in the control of cardiac arrhythmia: past and future.
    Singh BN
    Am J Cardiol; 1999 Nov; 84(9A):3R-10R. PubMed ID: 10568654
    [No Abstract]   [Full Text] [Related]  

  • 6. Evolution of the management of malignant ventricular tachyarrhythmias: the roles of drug therapy and implantable defibrillators.
    Kim SG
    Am Heart J; 1995 Nov; 130(5):1144-50. PubMed ID: 7484752
    [No Abstract]   [Full Text] [Related]  

  • 7. [Drug therapy of supraventricular and ventricular tachyarrhythmias].
    Hohnloser SH
    Internist (Berl); 1996 Jan; 37(1):45-52. PubMed ID: 8837827
    [No Abstract]   [Full Text] [Related]  

  • 8. [Therapy monitoring in cardiac arrhythmias: guidelines for evaluation of anti-arrhythmia effects].
    Hief C; Podczeck A; Frohner K; Nürnberg M; Kaltenbrunner W; Steinbach K
    Wien Med Wochenschr; 1994; 144(14-15):379-81. PubMed ID: 7825329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ventricular cardiac arrhythmias. New anti-arrhythmia agents].
    Scholz H
    Z Kardiol; 1996; 85 Suppl 6():91-6. PubMed ID: 9064988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anti-arrhythmic therapy of ventricular arrhythmias. Assessing benefit and risk].
    Haberl R; Steinbeck G
    Internist (Berl); 1993 May; 34(5):436-43. PubMed ID: 8509254
    [No Abstract]   [Full Text] [Related]  

  • 11. Current status of medical treatment of tachyarrhythmias.
    Shen WF
    Chin Med J (Engl); 1992 Oct; 105(10):796-802. PubMed ID: 1363312
    [No Abstract]   [Full Text] [Related]  

  • 12. Electrocardiographic predictors in the ESVEM trial: unsustained ventricular tachycardia, heart period variability, and the signal-averaged electrocardiogram.
    Anderson KP; Bigger JT; Freedman RA
    Prog Cardiovasc Dis; 1996; 38(6):463-88. PubMed ID: 8638028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of beta-blocker compared to combined amiodarone therapy secondary to ventricular tachyarrhythmias.
    Schupp T; Behnes M; Reiser L; Bollow A; Taton G; Reichelt T; Ellguth D; Engelke N; Ansari U; El-Battrawy I; Bertsch T; Weiß C; Nienaber C; Lang S; Akin M; Mashayekhi K; Borggrefe M; Akin I
    Int J Cardiol; 2019 Feb; 277():118-124. PubMed ID: 30473333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infarct related artery patency: relation to serial electropharmacological studies and outcome in patients with previous myocardial infarction and ventricular tachyarrhythmias.
    Hoppe UC; Haverkamp W; Breithardt G; Borggrefe M
    Pacing Clin Electrophysiol; 2000 May; 23(5):854-62. PubMed ID: 10833706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Invasive differential therapy of supraventricular and ventricular tachyarrhythmias].
    Perings C; Hennersdorf M; Klein RM; Vester EG; Strauer BE
    Internist (Berl); 1996 Jan; 37(1):60-73. PubMed ID: 8837829
    [No Abstract]   [Full Text] [Related]  

  • 16. [Heart failure and treatment of ventricular arrhythmias].
    Junga G; Duru F; Candinas R
    Praxis (Bern 1994); 1999 Feb; 88(6):215-22. PubMed ID: 10081339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implanted cardioverter-defibrillators are preferable to drugs as primary therapy in sustained ventricular tachyarrhythmias.
    Saksena S; Madan N; Lewis C
    Prog Cardiovasc Dis; 1996; 38(6):445-54. PubMed ID: 8638025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [How do you want to die? The therapeutic options in ventricular tachyarrhythmia at the end of the anti-arrhythmia drug era].
    Seipel L
    Z Kardiol; 1995 Oct; 84(10):787-90. PubMed ID: 7502564
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical significance of electrophysiologic drug testing in the longterm therapy of class I, III and IV antiarrhythmic drugs for recurrent ventricular tachyarrhythmia].
    Kasanuki H; Ohnishi S; Amamiya K; Umemura J; Shoda M; Hosoda S
    Jpn Circ J; 1992; 56 Suppl 5():1458-61. PubMed ID: 1291742
    [No Abstract]   [Full Text] [Related]  

  • 20. [Out-of- or in-hospital occurrences of malignant ventricular tachyarrhythmias: the prognostic significance in the population enrolled in the AVID study. Antiarrhythmic versus Implantable Defibrillators].
    Occhetta E
    Ital Heart J Suppl; 2000 Apr; 1(4):579-80. PubMed ID: 10832150
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.